Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Challenging CD30-positive lymphomas – Current challenges, new insights and future directions: Joining a conversation on CD30+ lymphomas

Leukemia Research, 9, 38, page 1003

CD30 is a therapeutic target in the management of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL). Brentuximab vedotin has demonstrated efficacy in the management of patients with R/R HL and sALCL, and may potentially be relevant in the management of other CD30+ lymphomas. This webcast is of a satellite symposium that takes the form of a forum and serves as a platform for looking at the latest clinical trials and exchanging information on the daily management of CD30+ lymphomas. It includes several case and panel discussions, as well as some interactive dialogue with the audience.

Discussions include current medical needs in the treatment of CD30+ haematological malignancies and current ongoing clinical trial data (including efficacy and safety) on novel treatment strategies for patients with HL, sALCL, and peripheral T-cell lymphoma (PTCL). The selection of eligible patients and optimal management of patients with R/R HL or sALCL receiving brentuximab vedotin in daily practice are addressed, including patient eligibility, dosing, optimal number of cycles, retreatment, and the management of side effects. Ongoing clinical trials in the use of CD30-targeted therapies in other haematological malignancies are also discussed in this webcast.

Complete footage of this webcast can be found here: http://cd30lymphoma.elsevierresource.com/

Financial disclosure

This symposium webcast and report are sponsored by an educational grant from Millennium: The Takeda Oncology Company.

Conflicts of interest

All faculty members were paid an honorarium for speaking/presenting at this symposium by Millennium: The Takeda Oncology Company. Christian Gisselbrecht has no further conflicts of interest to declare. Pier Luigi Zinzani has no further conflicts of interest to declare. Peter Borchmann has performed contracted research for Takeda. Francesco d’Amore has worked as a consultant for Takeda, Mundipharma, Kyowa Kirin, and CTI Life Sciences. Timothy M. Illidge has worked as a consultant for Takeda and Roche.


a Hôpital Saint-Louis, Paris, France

b University Hospital of Cologne, Cologne, Germany

c Aarhus University Hospital, Aarhus, Denmark

d Manchester University, Manchester, UK

e University of Bologna, Bologna, Italy

lowast Corresponding author.